Ascendis Pharma A/S (ASND) Stock Forecast & Price Target

$238.66 -7.48 (-3.04%)

Closing price 04:00 PM Eastern

Extended Trading

$238.31 -0.35 (-0.15%)

As of 05:49 PM Eastern

Compare

Ascendis Pharma A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
1

Hold
0

Buy
18

Based on 19 Wall Street analysts who have issued ratings for Ascendis Pharma A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 17 have given a buy rating, and 1 has given a strong buy rating for ASND.

Consensus Price Target

$291.33
22.07% Upside

According to the 19 analysts' twelve-month price targets for Ascendis Pharma A/S, the average price target is $291.33. The highest price target for ASND is $342.00, while the lowest price target for ASND is $255.00. The average price target represents a forecasted upside of 22.07% from the current price of $238.66.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ASND and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ascendis Pharma A/S and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ASND Analyst Ratings Over Time

Type	Current Forecast 5/8/25 to 5/8/26	1 Month Ago 4/8/25 to 4/8/26	3 Months Ago 2/7/25 to 2/7/26	1 Year Ago 5/8/24 to 5/8/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$291.33	$289.89	$270.76	$216.07
Forecasted Upside	22.07% Upside	24.31% Upside	21.88% Upside	35.35% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Buy

ASND Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ASND Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ascendis Pharma A/S Stock vs. The Competition

Type	Ascendis Pharma A/S	Medical Companies	S&P 500
Consensus Rating Score	2.95	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	22.15% Upside	842.59% Upside	15.51% Upside
News Sentiment Rating	Positive News See Recent ASND News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/16/2026	Bank of America 4 of 5 stars	Tazeen Ahmad 5 of 5 stars	Boost Target	Buy	$262.00 ➝ $292.00	+21.82%
4/9/2026	Wedbush 5 of 5 stars	Yun Zhong Not Rated	Reiterated Rating	Outperform	$273.00	+17.07%
3/16/2026	Jefferies Financial Group 2 of 5 stars	Kelly Shi Not Rated	Initiated Coverage	Buy	$290.00	+25.89%
3/4/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Thompson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$332.00	+37.54%
3/2/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$250.00 ➝ $275.00	+13.59%
3/2/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kalpit Patel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$260.00	+10.14%
3/2/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Li Watsek Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00	+27.08%
3/2/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Josh Schimmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$324.00	+38.02%
3/2/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Choi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$255.00	+9.21%
2/12/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$246.00 ➝ $262.00	+18.29%

2/12/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Maxwell Skor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$256.00	+15.58%
1/27/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$342.00	+43.22%
1/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
1/20/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derek Archila Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$322.00 ➝ $330.00	+60.33%
1/7/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
10/17/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$271.00	+30.90%
10/9/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$260.00 ➝ $264.00	+25.64%
8/8/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lebowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$243.00 ➝ $290.00	+51.44%
8/8/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$306.00 ➝ $307.00	+67.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:31 PM ET.

ASND Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Ascendis Pharma A/S is $291.33, with a high forecast of $342.00 and a low forecast of $255.00.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There is currently 1 sell rating, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ASND shares.

According to analysts, Ascendis Pharma A/S's stock has a predicted upside of 22.07% based on their 12-month stock forecasts.

Ascendis Pharma A/S has been rated by research analysts at Bank of America, Cantor Fitzgerald, Evercore, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Wedbush, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Ascendis Pharma A/S more than other "medical" companies. The consensus rating for Ascendis Pharma A/S is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ASND compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Ascendis Pharma A/S Recommendations

This page (NASDAQ:ASND) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Stock Forecast & Price Target

Ascendis Pharma A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ASND Analyst Ratings Over Time

ASND Analyst Recommendations By Month

ASND Price Targets by Month

Ascendis Pharma A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

ASND Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Ascendis Pharma A/S Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Stock Forecast & Price Target

Ascendis Pharma A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ASND Analyst Ratings Over Time

ASND Analyst Recommendations By Month

ASND Price Targets by Month

Ascendis Pharma A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

ASND Forecast - Frequently Asked Questions

What is Ascendis Pharma A/S's forecast for 2026?

Should I buy or sell Ascendis Pharma A/S stock right now?

Does Ascendis Pharma A/S's stock price have much upside?

What analysts cover Ascendis Pharma A/S?

Do Wall Street analysts like Ascendis Pharma A/S more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Ascendis Pharma A/S Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools